



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2010-020166-20/ Novartis Protocol ID CACZ885I2208

*A randomized, double-blind, multiple-dose, placebo-controlled, parallel group study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ACZ885 in patients with newly diagnosed type-1 diabetes mellitus (T1DM)*

Trial CACZ885I2208 was cancelled with no patient enrollment and as such, no results will be reported.